Russell Frank Company’s Sage Therapeutics SAGE Stock Holding History

Russell Frank Company’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-8,636	Closed	-$365K	–	3027
2015 Q3	$365K	Sell	8,636 -14,452	-63%	-$891K	﹤0.01%	2569
2015 Q2	$1.69M	Buy	+23,088	New	+$1.48M	﹤0.01%	2066

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Russell Frank Company's SAGE Position: Q4 2015 in Review

Russell Frank Company sold out of Sage Therapeutics (SAGE) in Q4 2015, closing a stake of 8,636 shares — an estimated $365K sold.

Russell Frank Company first reported a position in SAGE in Q2 2015 and held it in 2 quarters. The position peaked at $1.69M in Q2 2015. 137 funds tracked by Wall St. Rank hold SAGE as of Q4 2015.

Russell Frank Company reported no remaining Sage Therapeutics position as of Q4 2015 after selling out during the quarter.
Russell Frank Company sold 8,636 Sage Therapeutics shares in Q4 2015, an estimated $365K.
Russell Frank Company first reported a position in Sage Therapeutics in Q2 2015 and held it in 2 quarters.
Russell Frank Company's Sage Therapeutics position peaked at $1.69M in Q2 2015.
137 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2015.

Based on Russell Frank Company's 13F filing for Q4 2015, filed 27 Jan 2016.